{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:59Z","timestamp":1790775179032,"version":"4.1.0"},"reference-count":56,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Noonan syndrome is a heterogeneous congenital disorder. The main features are typical facial features, short stature and cardiac defects. The diagnosis is clinical: in 80% of patients with Noonan syndrome a genetic defect can be shown. Inheritance is predominantly autosomal dominant and seldom autosomal recessive. In 2001, PTPN11 was the first gene connected to Noonan syndrome, and until now, at least 20 other genes have been discovered. All genes code for proteins involved in the RAS-MAP-kinase pathway, and therefore, Noonan syndrome is one of the known RASopathies. Other RASopathies include neurofibromatosis and CFC syndrome. Short stature is one of the defining features of Noonan syndrome. The cause is not fully understood but is multifactorial. Other endocrinological features are confined to delayed puberty and hypogonadism in boys and males. To increase adult height, children with Noonan syndrome have been treated with human growth hormone since the 1990s. This seems to be beneficial in most of the children treated. In this narrative review, we describe the current knowledge on growth, endocrinological features and growth hormone treatment in patients with Noonan syndrome.<\/jats:p>","DOI":"10.3390\/jcm11072034","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:26:07Z","timestamp":1649157967000},"page":"2034","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Growth, Endocrine Features, and Growth Hormone Treatment in Noonan Syndrome"],"prefix":"10.3390","volume":"11","author":[{"given":"Jovanna","family":"Dahlgren","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Gothenburg, 41685 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-5921","authenticated-orcid":false,"given":"Cees","family":"Noordam","sequence":"additional","affiliation":[{"name":"Centre for Paediatric Endocrinology Zurich (PEZZ), 8006 Zurich, Switzerland"},{"name":"Department of Pediatrics, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajmg.1320210312","article-title":"Noonan syndrome: A review","volume":"21","author":"Mendez","year":"1985","journal-title":"Am. J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jmg.24.1.9","article-title":"Noonan syndrome","volume":"24","author":"Allanson","year":"1987","journal-title":"J. Med. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/000992289403300907","article-title":"Noonan syndrome. An update and review for the primary pediatrician","volume":"33","author":"Noonan","year":"1994","journal-title":"Clin. Pediatr."},{"key":"ref_4","first-page":"435","article-title":"Molecular Genetics of Noonan Syndrome and RASopathies","volume":"16","author":"Liao","year":"2019","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1399-0004.1986.tb00587.x","article-title":"Growth curves for height in Noonan syndrome","volume":"30","author":"Witt","year":"1986","journal-title":"Clin. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00441408","article-title":"Noonan syndrome: Growth and clinical manifestations in 144 cases","volume":"148","author":"Ranke","year":"1988","journal-title":"Eur. J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1530\/EJE-15-0922","article-title":"Growth patterns of patients with Noonan syndrome: Correlation with age and genotype","volume":"174","author":"Cessans","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1002\/ajmg.a.35519","article-title":"Growth standards of patients with Noonan and Noonan-like syndromes with mutations in the RAS\/MAPK pathway","volume":"158A","author":"Malaquias","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajmg.a.38649","article-title":"First-year growth in children with Noonan syndrome: Associated with feeding problems?","volume":"176","author":"Croonen","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm1084","article-title":"Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation","volume":"10","author":"Araki","year":"2004","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajmg.a.20502","article-title":"Adult height in Noonan syndrome","volume":"123A","author":"Noonan","year":"2003","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jpeds.2012.02.043","article-title":"Health and quality of life in adults with Noonan syndrome","volume":"161","author":"Binder","year":"2012","journal-title":"J. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/adc.2006.104547","article-title":"The natural history of Noonan syndrome: A long-term follow-up study","volume":"92","author":"Shaw","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"ref_14","first-page":"36","article-title":"Noonan syndrome: Growth to growth hormone\u2014The experience of observational studies","volume":"72","author":"Ranke","year":"2009","journal-title":"Horm. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0022-3476(96)70005-7","article-title":"Growth hormone treatment in Noonan syndrome: The National Cooperative Growth Study experience","volume":"128","author":"Romano","year":"1996","journal-title":"J. Pediatr."},{"key":"ref_16","first-page":"2291","article-title":"The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan\u2019s syndrome","volume":"81","author":"Cotterill","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2001.01188.x","article-title":"Growth hormone (GH) secretion in children with Noonan syndrome: Frequently abnormal without consequences for growth or response to GH treatment","volume":"54","author":"Noordam","year":"2001","journal-title":"Clin. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"737893","DOI":"10.3389\/fendo.2021.737893","article-title":"GH Responsiveness in Children With Noonan Syndrome Compared to Turner Syndrome","volume":"12","author":"Dahlgren","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1210\/jc.2005-0995","article-title":"PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome","volume":"90","author":"Binder","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1210\/jc.2005-0983","article-title":"Noonan syndrome: Relationships between genotype, growth, and growth factors","volume":"91","author":"Limal","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/s41467-021-21712-4","article-title":"Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans","volume":"12","author":"Gualtieri","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF03401289","article-title":"IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene","volume":"12","author":"Bertelloni","year":"2013","journal-title":"Hormones"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1073\/pnas.1119803109","article-title":"Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature","volume":"109","author":"Edouard","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1242\/dmm.006130","article-title":"Development of severe skeletal defects in induced SHP-2-deficient adult mice: A model of skeletal malformation in humans with SHP-2 mutations","volume":"4","author":"Bauler","year":"2011","journal-title":"Dis. Model. Mech."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/hmg\/ddy133","article-title":"Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth","volume":"27","author":"Tajan","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/adc.67.2.178","article-title":"A clinical study of Noonan syndrome","volume":"67","author":"Sharland","year":"1992","journal-title":"Arch. Dis. Child."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/EJE-18-0582","article-title":"Noonan syndrome males display Sertoli cell-specific primary testicular insufficiency","volume":"179","author":"Moniez","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1651-2227.2005.tb02081.x","article-title":"Improved final height with long-term growth hormone treatment in Noonan syndrome","volume":"94","author":"Osio","year":"2005","journal-title":"Acta Paediatr."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rezende, R.C., Noronha, R.M., Keselman, A., Quedas, E.P.S., Dantas, N.C.B., Andrade, N.L.M., Bertola, D.R., Malaquias, A.C., and Jorge, A.A.L. (2022). Delayed puberty phenotype observed in Noonan syndrome is more pronounced in girls than boys. Horm. Res. Paediatr.","DOI":"10.1159\/000522670"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1210\/jc.2008-2094","article-title":"Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone","volume":"94","author":"Romano","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1515\/JPEM.2008.21.11.1079","article-title":"Impaired Sertoli cell function in males diagnosed with Noonan syndrome","volume":"21","author":"Marcus","year":"2008","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-11-0092","article-title":"Testicular size development and reproductive hormones in boys and adult males with Noonan syndrome: A longitudinal study","volume":"165","author":"Westphal","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0022-3476(73)80482-2","article-title":"Noonan\u2019s syndrome and autoimmune thyroiditis","volume":"83","author":"Vesterhus","year":"1973","journal-title":"J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/JPEM.2003.16.2.217","article-title":"Noonan\u2019s syndrome and autoimmune diseases","volume":"16","author":"Svensson","year":"2003","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ajmg.a.35290","article-title":"Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies","volume":"158A","author":"Quaio","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_36","first-page":"24","article-title":"Noonan syndrome: The hypothalamo-adrenal and hypothalamo-gonadal axes","volume":"72","author":"Kelnar","year":"2009","journal-title":"Horm. Res."},{"key":"ref_37","first-page":"281","article-title":"Treatment with growth hormone (GH) in 3 cases of Noonan syndrome","volume":"39","author":"Cianfarani","year":"1987","journal-title":"Minerva Pediatr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000184618","article-title":"Growth hormone treatment in Noonan syndrome: Report of four cases who reached final height","volume":"44","author":"Municchi","year":"1995","journal-title":"Horm. Res."},{"key":"ref_39","first-page":"1953","article-title":"Growth hormone therapy and growth in children with Noonan\u2019s syndrome: Results of 3 years\u2019 follow-up","volume":"86","author":"MacFarlane","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_40","first-page":"889","article-title":"Growth hormone treatment in children with Noonan\u2019s syndrome: Four year results of a partly controlled trial","volume":"90","author":"Noordam","year":"2001","journal-title":"Acta Paediatr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-08-0413","article-title":"Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11","volume":"159","author":"Noordam","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000512429","article-title":"Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome","volume":"93","author":"Rohrer","year":"2020","journal-title":"Horm. Res. Paediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/JPEM.2008.21.3.267","article-title":"Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database","volume":"21","author":"Raaijmakers","year":"2008","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000371635","article-title":"The impact of growth hormone therapy on adult height in noonan syndrome: A systematic review","volume":"83","author":"Giacomozzi","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1507\/endocrj.EJ17-0313","article-title":"Efficacy and safety of two doses of Norditropin((R)) (somatropin) in short stature due to Noonan syndrome: A 2-year randomized, double-blind, multicenter trial in Japanese patients","volume":"65","author":"Ozono","year":"2018","journal-title":"Endocr. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1507\/endocrj.EJ19-0371","article-title":"Long-term efficacy and safety of two doses of Norditropin((R)) (somatropin) in Noonan syndrome: A 4-year randomized, double-blind, multicenter trial in Japanese patients","volume":"67","author":"Horikawa","year":"2020","journal-title":"Endocr. J."},{"key":"ref_47","first-page":"110","article-title":"Effects of growth hormone treatment on left ventricular dimensions in children with Noonan\u2019s syndrome","volume":"56","author":"Noordam","year":"2001","journal-title":"Horm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.hfc.2017.12.005","article-title":"Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathies","volume":"14","author":"Calcagni","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e210549","DOI":"10.1530\/EC-21-0549","article-title":"Cardiovascular safety of growth hormone treatment in Noonan syndrome: Real-world evidence","volume":"11","author":"Romano","year":"2022","journal-title":"Endocr. Connect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ejhg.2011.37","article-title":"Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation","volume":"19","author":"Jongmans","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/bjc.2015.75","article-title":"Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes","volume":"112","author":"Kratz","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","article-title":"The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease","volume":"106","author":"Kratz","year":"2005","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajmg.a.37379","article-title":"Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy","volume":"170A","author":"McWilliams","year":"2016","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"103617","DOI":"10.1016\/j.ejmg.2019.01.007","article-title":"Oligo-astrocytoma in LZTR1-related Noonan syndrome","volume":"63","author":"Jacquinet","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1158\/1078-0432.CCR-17-0631","article-title":"Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk","volume":"23","author":"Villani","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/2034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:48:36Z","timestamp":1760136516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/2034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11072034"],"URL":"https:\/\/doi.org\/10.3390\/jcm11072034","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]}}}